Looking beyond COVID-19 vaccine phase 3 trials | Nature Medicine
Coronavirus (COVID-19) Vaccines | CardioSmart – American College of Cardiology
Frontiers | Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It
Participants sought for COVID-19 vaccine trial for booster and variant protection
Homologous and Heterologous Covid-19 Booster Vaccinations | NEJM
Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial -
A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet
UC Davis and Pfizer partner on two new COVID-19 booster vaccine clinical trials
NIH clinical trial evaluating mixed COVID-19 vaccine schedules begins | National Institutes of Health (NIH)
Getting a Flu Vaccine and a COVID-19 Vaccine at the Same Time | CDC
Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV- BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study | Pediatric Research
Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with
PRACT: a pragmatic randomized adaptive clinical trial protocol to investigate a culturally adapted brief negotiational intervention for alcohol use in the emergency department in Tanzania | Trials | Full Text
FDA will not require clinical trial data to authorize redesigned COVID boosters -official | Reuters
Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial - eBioMedicine
Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years | NEJM
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
How To Improve Patient Recruitment In Clinical Trials? | Credevo Articles
COVID-19 Booster Vaccine Study | Suburban Hospital | Johns Hopkins Medicine
Monitoring Visits in Clinical Trials
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and ...
NIH begins clinical trial evaluating second COVID-19 booster shots in adults | National Institutes of Health (NIH)
Department of Health and Social Care on Twitter: "Everyone aged 16 and over is eligible for the #COVID19 booster from three months after their second dose. Book an appointment online or find
Virology Research Clinic - University of Washington
